Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135662 | 1.00 | LMNA (0.48) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL135660 | 1.00 | LMNA (0.48) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL134213 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL9820825 | 0.97 | TSHR (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6913949 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6914968 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6908741 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6916906 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6917784 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL10723734 | 0.97 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-9976165-B2 | Methods for increasing molecular diversity of polyketides and non-ribosomal proteins | ISOMERASE THERAPEUTICS, LTD. (GB) | 2018-05-22 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| CN-1310868-C | Process for producing trans-1, 4-cyclohexanedicarboxylic acid | MITSUBISHI CHEM CORP (JP) | 2007-04-18 | — | — | CN | disclosed |
| CN-1935773-A | Process for producing trans-1, 4-cyclohexanedicarboxylic acid | MITSUBISHI CHEM CORP (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| CN-1608042-A | Process for producing trans-1, 4-cyclohexanedicarboxylic acid | MITSUBISHI CHEM CORP (JP) | 2005-04-20 | — | — | CN | disclosed |
| US-20050014973-A1 | Process for producing trans-1,4-cyclohexanedicarboxylic acid | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1449822-A1 | METHOD FOR PRODUCING TRANS-1,4-CYCLOHEXANE DICARBOXYLIC ACID | Mitsubishi Chemical Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-4507290-A | CONTRACEPTIVE | WORLD HEALTH ORGANIZATION (CH) | 1985-03-26 | — | — | US | disclosed |
| US-4426314-A | CATALYST SUPPORT FOR COODINATION CATALYST, POLYMERICZATION OF OLEFINS | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1984-01-17 | — | — | US | disclosed |
| EP-0053900-A1 | Magnesium containing solid catalyst carrier, a catalyst and its use in polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | LMNA 4323/4885PLG 3783/4885PLAT 443/4885 |
| US-11746098-B2 | Proteasome activity enhancing compounds | PSMG3, PSMC1, PSMB11 | LMNA 2899/4885PLG 4011/4885PLAT 4476/4885 |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | LMNA 2899/4885PLG 4011/4885PLAT 4476/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | LMNA 1423/4885PLG 4218/4885PLAT 4538/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | LMNA 4393/4885PLG 3847/4885PLAT 1471/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | LMNA 4044/4885PLG 654/4885PLAT 479/4885 |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ROCK1, ROCK2, RHOA | LMNA 1225/4885PLG 3436/4885PLAT 3104/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | LMNA 4393/4885PLG 3847/4885PLAT 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.